Skip to main content
. 2023 Feb 24;15(3):623. doi: 10.3390/v15030623

Figure 1.

Figure 1

Study workflow for isolation and characterization of blood plasma derived EVs and ECs. (A) Description of experimental model. (B) Methodological workflow for isolation, and characterization of EVs and ECs. (C) Pie chart showing percent detectable miRNAs in the EVs and ECs for each treatment group. (D) The number of detectable miRNAs for the EVs and ECs at the Pre, 1 MPI and 5 MPI time points for VEH/SIV, VEH/SIV/ART, THC/SIV, THC/SIV/ART, and THC/no SIV treatment groups. (E) The number of detectable miRNAs for the EVs and ECs at 1 MPI (left) and 5 MPI (right) for VEH/SIV, VEH/SIV/ART, THC/SIV, THC/SIV/ART, and THC/no SIV treatment groups. To be included, miRNA count needed to be ≥1 for n = 3 RMs. Binary students’ t tests (Welch’s correction) were used to determine significant differences between EVs and ECs for each of the time points in each group. *** p < 0.005, ** p < 0.01, * p < 0.05, and ns = non-significant.